In a statement, the company said it would partner with Prasco Laboratories to distribute Colchicine Tablets, USP, an authorized generic version of Colcrys
Introducing an Authorized Generic of Colcrys
provides patients, pharmacists, and physicians with access to a therapeutically equivalent option to Colcrys
Tablets for the prevention and treatment of gout flares, stated Prasco chief executive officer, Chris Arington.
Gout Therapeutics Market to 2017 - Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys
to Drive Market provides in-depth analysis of the drivers and barriers that affect the global musculoskeletal therapeutics market.
Important Safety Information COLCRYS
can cause serious side effects or death if levels of COLCRYS
are too high in your body.
The FDA's approval of Colcrys
and the plans to ban the marketing of the older products has been sharply criticized by some clinicians who treat patients with gout because Colcrys
is significantly more expensive than the older, unapproved formulations.
Some pharmacies only have Colcrys
available," he added.
It is the Company's generic version of Takeda's Colcrys
, which is a prescription medicine used in adults to prevent and treat gout flares.
While Multaq is an antiarrhythmic drug for reducing the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF, Colcrys
is used for the prevention and treatment of gout flares.
Takeda provides multiple therapeutic options for gout patients including Colcrys
(colchicine, USP) for the treatment and prevention of flares associated with gout and Uloric (febuxostat), used to lower blood uric acid levels in adults with gout.
With the acquisition of URL Pharma earlier this year, Takeda has become a leader in gout therapy by adding Colcrys
to its portfolio.
Major marketed classes of products for treatment of gout include NSAIDs, corticosteroids, Colcrys
(Colchicines), Allopurinol, Probenecid, Uloric, Adenuric (febuxostat) and Krystexxa (Pegloticase).
Its leading product is Colcrys
(colchicine) - used to treat and prevent gout flares.
GBI Research has released its pharmaceutical research, "Gout Therapeutics Market to 2017 - Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys
to Drive Market", which provides insights into gout therapeutics sales and price forecasts until 2017.